247 REPEAT PROSTATE BIOPSY AND THE INCREMENTAL RISK OF CLINICALLY INSIGNIFICANT PROSTATE CANCER

Matthew J. Resnick(Vanderbilt University Medical Center), Thomas J. Guzzo(Hospital of the University of Pennsylvania), Alan J. Wein(University of Miami), Daniel Lee(Philadelphia University), S. Bruce Malkowicz(Philadelphia University), Keith VanArsdalen(University of Pennsylvania)
The Journal of Urology
March 23, 2010
10.1016/j.juro.2010.02.306
Cited by 2

Related Papers

Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years
|JAMA|2017|349
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
|The Journal of Urology|2020|268